key: cord-0732303-c1v9plef authors: Yan, Connie H.; Naveed, Maryam; Alobaidi, Ali; Kopfman, Miranda; Nutescu, Edith A.; Sharp, Lisa K.; Cannegieter, Dr Suzanne title: Association between transportation barriers and anticoagulation control among an inner‐city, low‐income population: A prospective observational cohort study date: 2021-10-31 journal: Res Pract Thromb Haemost DOI: 10.1002/rth2.12605 sha: a0bd04afa67ab65425ec7908f6cd08c60bf81115 doc_id: 732303 cord_uid: c1v9plef BACKGROUND: Anticoagulation with warfarin represents a transportation‐sensitive treatment state. Transportation barrier is a common reason for not using health care services. OBJECTIVE: To assess the association between transportation barriers to anticoagulation clinic and anticoagulation control (AC) among an inner‐city, low‐income population. PATIENTS/METHODS: Adults expected to be on chronic warfarin therapy were recruited from an ambulatory anticoagulation clinic. Participants completed a validated questionnaire that assessed transportation barriers to clinic, defined as self‐reported trouble getting transportation to a clinic and a composite score of the presence of transportation barriers. Suboptimal AC was defined as time in therapeutic range (TTR) <60% over 6 months. Prevalence ratios with 95% confidence intervals (CIs), adjusted for age, sex, and annual household income, described the association of transportation trouble and barriers with AC. RESULTS: Of 133 participants, 42.9% had suboptimal AC. Mean age was 60.4 (SD, 13.6) years, and the majority of participants were women (62.2%). Participants with transportation trouble were more likely to report being disabled/unable to work (63.6%) and annual household income <$15 000 (45.5%). Mean TTR was significantly lower for participants with transportation trouble compared to those without (53.8% [SD, 24.7%] vs 64.7% [SD, 25.0%]; P = .03). Participants reporting transportation trouble or at least one transportation barrier were 1.60 (95% CI, 1.07‐2.39) and 1.68 (95% CI, 1.01‐2.80) times more likely, respectively, to have suboptimal AC compared to those without. CONCLUSION: Inner‐city, low‐income individuals with transportation barriers were more likely to have suboptimal AC. Further research is warranted to evaluate the impact of alleviating patient‐specific transportation barriers on anticoagulation outcomes. • Associations between transportation barriers and patients' anticoagulation outcomes are unknown. • We conducted a cohort study of patients on chronic warfarin and managed at an urban anticoagulation clinic. • Patients with transportation barriers are more likely to have poor anticoagulation control. • It is important to screen and identify patients at high risk for transportation barriers. Transportation is a major barrier to timely access to medical care and medications. 1 In 2017, ≈5.8 million Americans missed or delayed medical care due to transportation issues. 2, 3 While specific transportation issues vary by geographic location (ie, rural vs urban), commonly reported travel barriers included lack of access to transportation (eg, vehicle, bus), associated cost, transport reliability, and commute safety (Figure 1 ). Transportation barriers may particularly impact the elderly, low-income individuals, or those residing further from health care providers. 1, 2, [4] [5] [6] [7] By missing medical appointments, patients are denied opportunities for assessment of medical conditions, adjustments to treatment, and escalation or deescalation of care. 1, 8 Although not all missed health care visits adversely impact health outcomes equally, evidence shows that missed medical appointments have been associated with increased emergency department visits, hospitalizations, and premature mortality. 1, 9, 10 Patients with vehicle ownership and higher Medicaid reimbursement for transportation had increased health care usage compared to those without. 1 Among low-income individuals, patients taking public transportation were twice as likely to miss their medical appointment compared to patients with private transportation. 11 Urban patients who used public transportation or walked to their hospital were less likely to have regular health care visits and more likely to delay care. 12 Anticoagulation with warfarin represents a transportationsensitive treatment state. Use of warfarin is limited by its narrow therapeutic index, major drug interactions, and variability in dose requirements. [13] [14] [15] Thus, warfarin therapy requires close monitoring of international normalized ratio (INR) and dose adjustment to ensure appropriate titration. The frequency of clinic visits to monitor warfarin dosing requirements vary by patient, but even stable patients typically require monthly visits for monitoring checks. Pharmacistled anticoagulation services have improved health care costs by lowering the frequency of thromboembolic and bleeding events, hospitalizations, and emergency department visits. 16 However, clinic no-shows remain an issue. To our knowledge, no published studies to date have examined the effects of transportation barriers on anticoagulation clinic attendance or associated patient health outcomes. 1, 17 This study aimed to address this gap by exploring the relationship between transportation to an anticoagulation clinic for warfarin monitoring and the level of anticoagulation control (AC) among an inner-city, low-income population. A prospective observational cohort study was conducted at a pharmacist-led antithrombosis clinic (ATC) located at an urban academic health care system in Chicago, Illinois. The ATC provided care for >500 patients treated with warfarin, among whom most were marginalized individuals due to race/ethnicity or socioeconomic Conclusion: Inner-city, low-income individuals with transportation barriers were more likely to have suboptimal AC. Further research is warranted to evaluate the impact of alleviating patient-specific transportation barriers on anticoagulation outcomes. anticoagulants, health outcome, health care services, transportation, warfarin Written informed consent and Health Insurance Portability and Accountability Act authorization were obtained from all participants before completing the one-time questionnaire administered by the RAs. All patient/personal identifiers were removed or disguised so the patient/person(s) described are not identifiable and cannot be identified through the details of the study. Compensation of $10 cash was provided at completion of the questionnaire. This study had full approval by the University of Illinois at Chicago's institutional review board. Transportation barriers were measured using a modified version of a 14-item validated questionnaire that captures mode of transportation options specific to urban environments and associated barriers. 18 Two scores resulted. The first reflected the amount of trouble Participants' warfarin laboratory values (eg, INR) were abstracted from the EMR during the 6-month follow-up period. AC was measured as percentage of time in therapeutic range (TTR) and calculated using the Rosendaal linear interpolation method. 21 A minimum of two reported INRs were needed to calculate the TTR. Suboptimal AC was defined as a TTR <60%; TTR ≥60% was considered optimal AC. Previous literature has reported a TTR <60% as clinically inefficient warfarin therapy or limited treatment benefit to patients. 22, 23 Participants who discontinued warfarin therapy during follow-up were excluded from analysis. Index and categorized as follows: 0, no comorbidity; 1 to 2, mild comorbidity; 3 to 4, moderate comorbidity; and ≥5, severe comorbidity. 25 Based on participants' indication for warfarin therapy, the following risk factors were calculated: risk of stroke in atrial fibrillation using the CHAD 2 DS 2 -VASc, risk of recurrent venous thromboembolism using the Disability of the Arm, Shoulder, and Hand score, and outpatient bleeding risk index. All data were recorded into Research Electronic Data Capture. 26 Descriptive statistics were calculated for sociodemographics, clinical characteristics, and travel parameters. Group differences were assessed using student t tests for continuous variables, and chisquare or Fisher's exact test for categorical variables, at a significance level of 0.05. Log-binomial models were used to estimate prevalence ratios with 95% confidence intervals (CIs) to assess the impact of trouble getting transportation to a clinic and presence of transportation barriers on AC. When log-binomial models failed to converge, Poisson regressions with robust variance were used. 27 Two minimally adjusted models were selected a priori: model 1, adjusted by age and sex; and model 2, adjusted by annual household income. Fully adjusted models were adjusted by age, sex, and annual household income, which were selected a priori and based on a backward selection approach. Statistical analyses were conducted using SAS version 9.4 (SAS Institute). 28 In the sensitivity analysis, the optimal AC threshold was varied from 60% to 50%, 55%, 65%, and 70% TTR. These TTR thresholds also reflect the range of TTR ranges reported in other studies. 22 over the 6-month period divided by the total number of INR values reported over the same period. 29 Optimal AC thresholds were the same as the main analyses (eg, variation from 50% to 70%). Sensitivity analyses were conducted by log-binomial and Poisson regression models adjusted by age, sex, and annual household income. In total, 144 participants provided consent and completed the questionnaire ( Figure 2 ). Eleven participants stopped warfarin therapy during the 6-month follow-up and were excluded from analysis. The majority of participants were African American (71.4%) and women (62.2%), with mean age of 60.4 (SD, 13.6) years (Table 1) . Mean duration of warfarin therapy was 78.5 (SD, 72.2) months, or ≈6.5 years. During the 6-month follow-up, participants on average In sensitivity analyses, no statistically significant trends or associations were observed between trouble getting transportation to a clinic (except for when TTR and INR in range was 65%) or having transportation barriers (except when TTR was 55%) and AC outcomes when the %TTR thresholds were varied (Figures S1 and S2) . In an inner-city population of marginalized individuals on long-term warfarin management, those reporting trouble getting transportation to a clinic or reporting at least one transportation barrier were twice as likely to experience suboptimal AC over a 6-month observation period than those without. Over half of participants without transportation trouble reported at least one transportation barrier. This finding highlights an obvious, yet often overlooked point in the study of transportation in health care: barriers must be considered in conjunction with resources that enable the individual to overcome them. For example, cold weather may be a barrier; however, individuals with vehicle access who can ambulate freely may be able to overcome the weather challenges, whereas others may not. Furthermore, this suggests that perception of "trouble getting transportation to a clinic" and specific transportation barriers may reflect two separate aspects of transportation. The most common barriers in our sample were weather and a lack of feeling safe in the commute to clinic. These barriers reflect characteristics of our urban sample, which was largely older women While self-reported round-trip costs from a participant's residence to ATC was not associated with AC, travel cost was reported as a barrier significantly more often among participants with suboptimal AC. Medical-related transportation is considered a direct nonmedical cost that, while covered under Medicaid, is not reimbursed by all insurance plans. For individuals struggling financially, the out-of-pocket expense of transportation is a fundamental barrier and considered a social determinant of health. 2 In our study, individuals reporting cost as a barrier to ATC appointments paid over twice the amount for transportation to each visit than those who could manage the transportation costs. Considering that patients on warfarin require monthly to weekly clinic appointments, costs add up. In a separate study at a metropolitan anticoagulation clinic, transportation costs for a single clinic visit were estimated to be nearly $11 per patient, which translated to between $130 and $560 annually depending on visit frequency. 31 For economically marginalized populations, the financial burden of transportation may simply be too high. This is not unique to warfarin. In a small study of HIV/AIDS patients, lack of money for transportation was a key factor for missed antiretroviral doses and missed medical appointments. 32 While some health plans include reimbursement policies for nonemergency medical transportation (NEMT), the financial burden to access such benefits and other restrictions can impact utility. 33 In the context of health care, ride-share services (eg, Uber, Lyft) have been increasingly adopted as a strategy to address pa- Among a sample of inner-city, low-income individuals on chronic warfarin therapy, trouble getting transportation to a clinic and selfreported transportation barriers were nearly twice as likely to have suboptimal AC. The multifaceted nature of warfarin therapy necessitates frequent visits to clinic for management. Transportation barriers can disrupt anticoagulation monitoring and dose adjustments. This study offers some insights into potential screening questions that may identify patients at highest risk. It is imperative to recognize that transportation, while not a medical condition, is still an important component of adequate anticoagulation management for patients. We thank the Anticoagulation Center faculty and students for their significant contributions in patient recruitment and data collection All authors contributed to the study design, acquisition and analysis and interpretation of the data, writing and reviewing of the manuscript, and decision to submit manuscript for publication. CY, MN, NK, EN, and LS declare no conflicts of interest. AA is an employee of AbbVie, Inc. and may own stocks/shares in the company. Connie H. Yan https://orcid.org/0000-0003-1467-4666 Ali Alobaidi https://orcid.org/0000-0002-0720-7894 Edith A. Nutescu https://orcid.org/0000-0002-2651-0020 Lisa K. Sharp https://orcid.org/0000-0002-7809-9042 Edith A. Nutescu @EdithNutescu Lisa K. Sharp @Sharpscience Traveling towards disease: transportation barriers to health care access Social determinants of health series: transportation and the role of hospitals Transportation barriers to health care in the United States: findings from the national health interview survey Access to care: development of a medication access framework for quality measurement Barriers to health care access among the elderly and who perceives them Coordinating community planning for transportation and health Cost-benefit analysis of providing non-emergency medical transportation Access to health care and nonemergency medical transportation two missing links Increased frequency of no-shows in residents' primary care clinic is associated with more visits to the emergency department Morbidity, mortality and missed appointments in healthcare: a national retrospective data linkage study Transportation to clinic: findings from a pilot clinic-based survey of low-income suburbanites Obstacles predicting lack of a regular provider and delays in seeking care for patients at an urban public hospital Warfarin: almost 60 years old and still causing problems National trends in oral anticoagulant use in the United States National trends in ambulatory oral anticoagulant use Impact of warfarin persistence on health-care utilization and costs among patients with atrial fibrillation managed in anticoagulation clinics in the United States Impact of transportation interventions on health care outcomes: a systematic review Measuring health-related transportation barriers in urban settings Applications of PROC GEOCODE and incorporation of census block-level data PROC GEOCODE: now with street-level geocoding A method to determine the optimal intensity of oral anticoagulant therapy Time in therapeutic range Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range Development of a brief test to measure functional health literacy A new method of classifying prognostic comorbidity in longitudinal studies: development and validation Research electronic data capture (REDCap)-A metadata-driven methodology and workflow process for providing translational research informatics support Easy SAS calculations for risk or prevalence ratios and differences Time in the therapeutic range for patients taking warfarin in clinical trials Are differences in travel time or distance to healthcare for adults in global north countries associated with an impact on health outcomes? A systematic review Transportation cost of anticoagulation clinic visits in an urban setting Transportation costs impede sustained adherence and access to HAART in a clinic population in southwestern Uganda: a qualitative study Restricting Medicaid payments for transportation: effects on inner-city patients' health care Ridesharing services help mHealth programs improve care coordination Doing more for patients and healthcare organizations amid the COVID-19 crisis Association of rideshare-based transportation services and missed primary care appointments: a clinical trial A systematic review of interventions to minimize transportation barriers among people with chronic diseases Selfmonitoring and self-management of oral anticoagulation In-home compared with in-clinic warfarin therapy monitoring in mechanical heart valves: a population-based study Anticoagulation patient self-monitoring in the United States: considerations for clinical practice adoption Distance as a barrier to cancer diagnosis and treatment: review of the literature